Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.54 |
| ▸ | RARA | P10276 | 2/20 | 0.54 |
| ▸ | RARG | P13631 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412567 | 0.86 | LMNA (0.59) | RARBRARARARGPTGS2LMNA | |
| SCHEMBL30641680 | 0.82 | RARB (0.60) | RARBRARARARGLMNA | |
| SCHEMBL16534058 | 0.82 | RARB (0.60) | RARBRARARARGLMNA | |
| SCHEMBL17680344 | 0.81 | LMNA (0.49) | KIF11PTGS2LMNA | |
| SCHEMBL2342255 | 0.80 | KIF11 (0.59) | KIF11RARBRARARARGLMNA | |
| SCHEMBL719665 | 0.80 | NPC1 (0.52) | KIF11PTGS2LMNA | |
| SCHEMBL10052771 | 0.80 | MCL1 (0.61) | RARBRARARARGLMNA | |
| SCHEMBL4652842 | 0.79 | RARB (0.58) | RARBRARARARGLMNA | |
| SCHEMBL31725051 | 0.79 | ACMSD (0.63) | RARBRARARARGLMNA | |
| SCHEMBL121429 | 0.79 | ACMSD (0.63) | RARBRARARARGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | KIF11 3118/4885RARB 1253/4885RARA 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.